Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002100:Cachexia / Q000139:chemically induced*; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D002908:Chronic Disease; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D011412:Propanolamines / Q000627:therapeutic use; D011446:Prospective Studies; D012720:Severity of Illness Index; D013318:Stroke Volume / Q000187:drug effects; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D015415:Biomarkers; D002227:Carbazoles; D007328:Insulin; D020738:Leptin; D011412:Propanolamines; D000077261:Carvedilol; D008790:Metoprolol; D009638:Norepinephrine